Bengaluru, January 6, 2026: Biocon Limited (BSE: 532523 | NSE: BIOCON) on Monday completed a major share swap and cash acquisition transaction, significantly strengthening its control over subsidiary Biocon Biologics Limited. The transaction involved both preferential allotment of equity shares and acquisition of shares from existing investors.
Key Transaction Highlights
Biocon completed the acquisition of 26.19 crore equity shares of Biocon Biologics from multiple investors and, in return, issued 17.13 crore equity shares of Biocon on a preferential basis. The equity shares were allotted at an issue price of ₹405.78 per share, fully paid-up, with a face value of ₹5 each.Details of Share Swap and Allotment
| Allottee | BBL Shares Acquired | Biocon Shares Allotted | Post-Allotment Stake |
|---|---|---|---|
| Mylan Inc. | 14,90,56,984 | 9,19,67,019 | 6.10% |
| Serum Institute Life Sciences Pvt Ltd | 7,89,02,725 | 5,54,48,765 | 3.68% |
| Tata Capital Growth Fund II | 88,30,456 | 62,05,589 | 0.41% |
| Activ Pine LLP | 2,51,27,315 | 1,76,58,180 | 1.17% |
| Total | 26,19,17,480 | 17,12,79,553 | 11.36% |
Equity Capital Expansion
Following the allotment, Biocon’s issued, subscribed and paid-up equity share capital increased as follows:| Particulars | Before Allotment | After Allotment |
|---|---|---|
| Paid-up Equity Capital | ₹668.48 crore | ₹754.12 crore |
| No. of Equity Shares | 133.70 crore | 150.82 crore |
| Face Value | ₹5 per share | ₹5 per share |
Cash Acquisition from Mylan
In addition to the share swap, Biocon also completed a cash acquisition of 7.18 crore equity shares of Biocon Biologics from Mylan Inc. for a consideration of USD 200 million. This forms part of a larger USD 400 million cash transaction approved earlier, with the remaining tranche to be executed subsequently.About the Company
Biocon Limited is a leading global biopharmaceutical company headquartered in Bengaluru, engaged in the discovery, development, and manufacture of biologics, biosimilars, and small molecule APIs. The company is listed on both the BSE and NSE and has a strong presence across key global markets, including the US, Europe, and emerging economies.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.